As we've
seen quite a lot of compounts being studied during the past two or three years,
I think it's to look how much hype or hope there is.
This list
remains incomplete, I know, but it shows that our hopes are mixed with lots of
hype. And this list is my personal interpretation; someone might disagree and
should do so in the commentary part. Red stands for problems or that I don't
think it will develop into a drug on the market. Yellow stands for might
develop into a drug, still to early. Though I still have my doubts in
fostamatinib (lake of showing effect on reducing radiographic progression), I
have put fosta on yellow again as new results have been shown.
I think that too many
pharmaceutical companies tried to run for a small molecule, which is easier to
produce, but might be sold at a high price.
I hope that we'll get these
drugs in the future, though well tested, safe, and not at the top pricing drug
companies expect.
Xeljanz right now stands
alone on the U.S. market (green). EMEA hasn't approved yet and the European
market will have to wait for another while as studies on radiographic
progression take time. Even if there is much hype, I hope for Xeljanz at least
to make it to the European market.
But maybe the future isn't
as dim as my list seems to predict. Concerning rheumatology we're living in
exciting times.
For an older text you might look here: http://rheumatologe.blogspot.de/2013/06/protein-kinase-inhibitors-hype-or-hope.html
No comments:
Post a Comment